EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality

Matthew A Sherman iD, Payam Noroozi Farhadi, Katherine Pak, Edward P Trieu, Kakali Sarkar, Ira N Targoff, Megan L Neely, Andrew L Mammen iD, Lisa G Rider iD, Childhood Myositis Heterogeneity Collaborative Study Group

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Matthew A Sherman und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland. Hauptthemen laut MEDLINE: Autoantibodies, Myositis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NIEHS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Myositis‐associated autoantibodies (MAAs) have been associated with overlap myositis, certain disease manifestations such as interstitial lung disease (ILD), and worse prognosis in the idiopathic inflammatory myopathies. MAAs overall remain largely uncharacterized in patients with juvenile‐onset myositis. Moreover, it is unknown whether the number of MAAs is associated with disease severity.

Methods

Patients with juvenile myositis in cross‐sectional natural history studies who underwent testing for myositis autoantibodies were included. Demographics, myositis autoantibodies, clinical characteristics, medications received, and outcomes of those with and without MAAs were compared. Multivariable logistic regression was performed to determine whether the number of MAAs detected was associated with severe disease features.

Results

Among 551 patients, 36% had an MAA and 13% had more than one MAA. Among those who were MAA positive, there was a higher frequency of overlap myositis (18% vs 5.9%, P < 0.001). MAA positivity was associated with certain clinical features, including Raynaud phenomenon (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.41–4.28) and ILD (OR 3.43, 95% CI 1.75–6.96), as well as a chronic disease course (OR 1.72, 95% CI 1.10–2.72) and mortality (OR 3.76, 95% CI 1.72–8.43). The number of MAAs was also associated with mortality (OR 1.83, 95% CI 1.16–2.86).

Conclusion

MAAs were prevalent in a large cohort of patients with juvenile myositis. ILD, refractory disease, and mortality were associated with MAA positivity. Prospective studies are needed to determine whether early detection of MAAs may lead to improved outcomes for patients with juvenile myositis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesMyositisHumansMaleFemaleChildAdolescentCross-Sectional StudiesDermatomyositisSeverity of Illness IndexLung Diseases, InterstitialLogistic ModelsChild, PreschoolRaynaud Disease

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
  • National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.
  • Oklahoma Medical Research Foundation, Oklahoma City.
  • Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City.
  • Duke University School of Medicine, Durham, North Carolina.
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, and Johns Hopkins University School of Medicine, Baltimore, Maryland.

ORCID-Profile: Matthew A Sherman, Andrew L Mammen, Lisa G Rider

Förderung

  • NIAMS NIH HHS
  • NIEHS NIH HHS
  • Intramural NIH HHS
  • NIH
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Environmental Health Sciences
  • National Institutes of Health

Zitieren

APA

Sherman, M. A., Noroozi Farhadi, P., Pak, K., Trieu, E. P., Sarkar, K., Targoff, I. N., Neely, M. L., Mammen, A. L., Rider, L. G., & Childhood Myositis Heterogeneity Collaborative Study Group (2024). Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis & Rheumatology. https://doi.org/10.1002/art.42813

Vancouver

Sherman MA, Noroozi Farhadi P, Pak K, Trieu EP, Sarkar K, Targoff IN, et al. Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis & Rheumatology. 2024. doi:10.1002/art.42813

BibTeX
@article{Sherman2024,
  author = {Sherman, Matthew A and Noroozi Farhadi, Payam and Pak, Katherine and Trieu, Edward P and Sarkar, Kakali and Targoff, Ira N and Neely, Megan L and Mammen, Andrew L and Rider, Lisa G and Childhood Myositis Heterogeneity Collaborative Study Group, Childhood Myositis Heterogeneity Collaborative Study Group},
  title = {Myositis‐Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42813}
}
Kostenlos starten →